BRaf inhibitors, dabrafenib and SB590885, enhance ERK1/2 signalling in cardiomyocytes and increase angiotensin II-induced cardiac hypertrophy.
29 April 2017 (08:30 - 17:30)
Organised by:
Abstract
Slides
About the speaker
University of Reading, Reading (United Kingdom of Great Britain & Northern Ireland)
9 More presentations in this session
Access the full session
The Event
Heart Failure 2017 - 4th World Congress on Acute Heart Failure
29 April 2017
08:30 CET
